DK1280803T3 - Krystallinsk form II af cabergolin - Google Patents

Krystallinsk form II af cabergolin

Info

Publication number: DK1280803T3
Authority: DK; Denmark
Prior art keywords: cabergoline; crystalline form; crystalline
Prior art date: 2000-03-24

Application number

DK01915373T

Other languages

English (en)

Inventor

Attilio Tomasi

Stefania Magenes

Giuliano Ramella

Mario Ungari

Marco Pandolfi

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-24

Filing date

2001-03-19

Publication date

2005-01-24

2001-03-19 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2005-01-24 Application granted granted Critical

2005-01-24 Publication of DK1280803T3 publication Critical patent/DK1280803T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK01915373T 2000-03-24 2001-03-19 Krystallinsk form II af cabergolin DK1280803T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0007307.2A GB0007307D0 (en)	2000-03-24	2000-03-24	Crystalline form \|\| of cabergoline

Publications (1)

Publication Number	Publication Date
DK1280803T3 true DK1280803T3 (da)	2005-01-24

Family

ID=9888432

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01915373T DK1280803T3 (da)	2000-03-24	2001-03-19	Krystallinsk form II af cabergolin

Country Status (31)

Country	Link
US (2)	US6673806B2 (da)
EP (1)	EP1280803B1 (da)
JP (1)	JP2003528874A (da)
KR (1)	KR20020081492A (da)
CN (1)	CN1221550C (da)
AR (1)	AR048279A1 (da)
AT (1)	ATE282038T1 (da)
AU (1)	AU783064B2 (da)
BR (1)	BR0109508A (da)
CA (1)	CA2399540A1 (da)
CZ (1)	CZ20023177A3 (da)
DE (1)	DE60107074T2 (da)
DK (1)	DK1280803T3 (da)
EA (1)	EA004376B1 (da)
EE (1)	EE200200544A (da)
ES (1)	ES2231461T3 (da)
GB (1)	GB0007307D0 (da)
HK (1)	HK1052692B (da)
HU (1)	HUP0300389A3 (da)
IL (1)	IL151670A0 (da)
MX (1)	MXPA02009284A (da)
MY (1)	MY126071A (da)
NO (1)	NO20024527D0 (da)
NZ (1)	NZ521314A (da)
PE (1)	PE20011087A1 (da)
PL (1)	PL358252A1 (da)
PT (1)	PT1280803E (da)
SI (1)	SI1280803T1 (da)
SK (1)	SK13572002A3 (da)
WO (1)	WO2001072747A1 (da)
ZA (1)	ZA200207151B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0007309D0 (en) *	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form V\|\| of cabergoline
GB0007307D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form \|\| of cabergoline
GB0007308D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
DE10053397A1 (de)	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
PL374503A1 (en) *	2002-03-15	2005-10-31	Pharmacia Corporation	Process for preparing crystalline form i of cabergoline
IL155545A (en) *	2003-04-21	2009-12-24	Finetech Pharmaceutical Ltd	Solvate form of cabergoline
CA2525104A1 (en) *	2003-05-08	2004-11-25	Ivax Pharmaceuticals S.R.O.	Polymorphs of cabergoline
GB0409785D0 (en) *	2004-04-30	2004-06-09	Resolution Chemicals Ltd	Preparation of cabergoline
US7339060B2 (en)	2005-03-23	2008-03-04	Resolution Chemicals, Ltd.	Preparation of cabergoline
GB0505965D0 (en)	2005-03-23	2005-04-27	Resolution Chemicals Ltd	Preparation of cabergoline
EP1953157A1 (en) *	2007-01-31	2008-08-06	LEK Pharmaceuticals D.D.	New crystal form of cabergoline
US20130163062A1 (en)	2011-12-22	2013-06-27	Qualcomm Mems Technologies, Inc.	Mechanical smart window with continuously tunable transmission

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US187013A (en) *		1877-02-06		Improvement in ovens for gas-stoves
US144516A (en) *		1873-11-11		Improvement in faucets
US149067A (en) *		1874-03-31		Improvement in steam-engine valve-gears
US4526892A (en)	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en)	1981-08-11	1985-04-11	Erba Farmitalia	Ergoline derivatives
GB0007307D0 (en) *	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form \|\| of cabergoline
GB0007308D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
GB0007309D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form V\|\| of cabergoline
GB0007376D0 (en)	2000-03-28	2000-05-17	Knoll Ag	Therapeutic agents

2000
- 2000-03-24 GB GBGB0007307.2A patent/GB0007307D0/en not_active Ceased
2001
- 2001-02-26 PE PE2001000198A patent/PE20011087A1/es not_active Application Discontinuation
- 2001-03-19 ES ES01915373T patent/ES2231461T3/es not_active Expired - Lifetime
- 2001-03-19 IL IL15167001A patent/IL151670A0/xx unknown
- 2001-03-19 SK SK1357-2002A patent/SK13572002A3/sk unknown
- 2001-03-19 AR ARP010101262A patent/AR048279A1/es unknown
- 2001-03-19 MX MXPA02009284A patent/MXPA02009284A/es active IP Right Grant
- 2001-03-19 AT AT01915373T patent/ATE282038T1/de not_active IP Right Cessation
- 2001-03-19 DK DK01915373T patent/DK1280803T3/da active
- 2001-03-19 HU HU0300389A patent/HUP0300389A3/hu unknown
- 2001-03-19 EA EA200201017A patent/EA004376B1/ru not_active IP Right Cessation
- 2001-03-19 DE DE60107074T patent/DE60107074T2/de not_active Expired - Fee Related
- 2001-03-19 BR BR0109508-0A patent/BR0109508A/pt not_active Application Discontinuation
- 2001-03-19 SI SI200130276T patent/SI1280803T1/xx unknown
- 2001-03-19 PL PL01358252A patent/PL358252A1/xx unknown
- 2001-03-19 CZ CZ20023177A patent/CZ20023177A3/cs unknown
- 2001-03-19 JP JP2001570657A patent/JP2003528874A/ja active Pending
- 2001-03-19 NZ NZ521314A patent/NZ521314A/en unknown
- 2001-03-19 AU AU42482/01A patent/AU783064B2/en not_active Ceased
- 2001-03-19 CA CA002399540A patent/CA2399540A1/en not_active Withdrawn
- 2001-03-19 WO PCT/EP2001/003098 patent/WO2001072747A1/en active IP Right Grant
- 2001-03-19 PT PT01915373T patent/PT1280803E/pt unknown
- 2001-03-19 US US10/239,562 patent/US6673806B2/en not_active Expired - Fee Related
- 2001-03-19 KR KR1020027012583A patent/KR20020081492A/ko not_active Application Discontinuation
- 2001-03-19 EP EP01915373A patent/EP1280803B1/en not_active Expired - Lifetime
- 2001-03-19 CN CNB01806471XA patent/CN1221550C/zh not_active Expired - Fee Related
- 2001-03-19 EE EEP200200544A patent/EE200200544A/xx unknown
- 2001-03-22 MY MYPI20011363A patent/MY126071A/en unknown
2002
- 2002-09-05 ZA ZA200207151A patent/ZA200207151B/en unknown
- 2002-09-20 NO NO20024527A patent/NO20024527D0/no unknown
2003
- 2003-06-27 HK HK03104604.7A patent/HK1052692B/zh not_active IP Right Cessation
- 2003-10-31 US US10/698,664 patent/US6800635B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CZ20023177A3 (cs)	2003-03-12
GB0007307D0 (en)	2000-05-17
HUP0300389A2 (hu)	2003-07-28
NZ521314A (en)	2004-05-28
AU783064B2 (en)	2005-09-22
HUP0300389A3 (en)	2004-08-30
HK1052692B (zh)	2006-03-03
MXPA02009284A (es)	2003-03-12
EA200201017A1 (ru)	2003-02-27
DE60107074D1 (de)	2004-12-16
ATE282038T1 (de)	2004-11-15
EP1280803B1 (en)	2004-11-10
JP2003528874A (ja)	2003-09-30
US20030187013A1 (en)	2003-10-02
BR0109508A (pt)	2002-12-17
CN1418213A (zh)	2003-05-14
IL151670A0 (en)	2003-04-10
SI1280803T1 (en)	2005-04-30
ZA200207151B (en)	2003-09-05
ES2231461T3 (es)	2005-05-16
EP1280803A1 (en)	2003-02-05
HK1052692A1 (en)	2003-09-26
WO2001072747A1 (en)	2001-10-04
US6673806B2 (en)	2004-01-06
EE200200544A (et)	2004-04-15
NO20024527L (no)	2002-09-20
SK13572002A3 (sk)	2003-04-01
KR20020081492A (ko)	2002-10-26
US20040072855A1 (en)	2004-04-15
PL358252A1 (en)	2004-08-09
CA2399540A1 (en)	2001-10-04
AR048279A1 (es)	2006-04-19
US6800635B2 (en)	2004-10-05
DE60107074T2 (de)	2005-10-20
EA004376B1 (ru)	2004-04-29
CN1221550C (zh)	2005-10-05
PE20011087A1 (es)	2001-10-04
NO20024527D0 (no)	2002-09-20
PT1280803E (pt)	2005-02-28
MY126071A (en)	2006-09-29
AU4248201A (en)	2001-10-08

Publication	Publication Date	Title
DK1169314T3 (da)	2002-10-14	Krystallinsk base af citalopram
IS7007A (is)	2003-10-30	Kristallaform af asiþrómýsíni
DK1438306T3 (da)	2014-06-23	Derivater af UK-2A
DK1307181T3 (da)	2006-01-30	Hidtil ukendte sammensætninger af minoxidil
IS3019B (is)	2020-02-15	Ný kristölluð og myndlaus form af tríasól(4,5-D)pýrímídínefnasambandi
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
DK1149090T3 (da)	2003-06-30	Ny krystallinsk form af kaliumsalt af (S)-omeprazol
IS7103A (is)	2004-01-12	Blanda af amínópýrimidínefnasamböndum
DK1107980T3 (da)	2003-04-22	Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
IS5640A (is)	2000-09-26	Ný kristalla form af Bensímídazól efnasambandi gegn veirum
DK1280803T3 (da)	2005-01-24	Krystallinsk form II af cabergolin
DK1142477T3 (da)	2004-10-11	Sammensætninger med reguleret frigivelse
DK1272489T3 (da)	2003-12-15	Fremgangsmåde til præparation af cabergolins krystallinske form I
IS6215A (is)	2001-12-27	Að mestu leyti kristallað form af melagatrani
PT1322592E (pt)	2004-12-31	Derivados substituidos de 1-aminobutan-3-ol
IS5821A (is)	2001-01-23	Kristalluð form af ósanetant
IS6127A (is)	2001-10-26	Ný kristölluð form af makrólíð sýklalyfi
IS6620A (is)	2002-11-14	Nýr fjölgervingur V af tórasemíði
NO20030416L (no)	2003-02-05	Krystallinsk terapeutisk forbindelse
SE0001422D0 (sv)	2000-04-17	Crystalline form
SE0001187D0 (sv)	2000-04-03	Crystalline form
DK1282588T3 (da)	2005-07-25	Fremstilling af hydroxyforbindelser
DK1191025T3 (da)	2005-08-01	Krystaller af lansoprazol
DK1169054T3 (da)	2004-11-22	Prognose af PTP LAR-relaterede sygdomme